Published in World J Surg on December 01, 2008
Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol (2009) 1.12
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer (2013) 0.97
Routine lymph node dissection may be not suitable for all intrahepatic cholangiocarcinoma patients: results of a monocentric series. World J Gastroenterol (2013) 0.91
Long-term survival after resection of mass-forming type intrahepatic cholangiocarcinoma directly infiltrating the transverse colon and sequential brain metastasis: Report of a case. Surg Today (2011) 0.90
Staging of peripheral-type intrahepatic cholangiocarcinoma: appraisal of the new TNM classification and its modifications. World J Surg (2011) 0.88
Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management. Gastroenterol Res Pract (2015) 0.87
Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg (2011) 0.87
Factors affecting survival after resection of intrahepatic cholangiocarcinoma. Surg Today (2014) 0.85
Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. BMC Cancer (2015) 0.84
Surgical management of proximal bile duct cancers. Langenbecks Arch Surg (2012) 0.83
The effect of wide resection margin in patients with intrahepatic cholangiocarcinoma: A single-center experience. Medicine (Baltimore) (2016) 0.80
Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively- determined anatomic invasion level and number of tumors. Dig Dis Sci (2014) 0.79
Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach. Dis Markers (2015) 0.77
Solitary rib recurrence of hilar cholangiocarcinoma 10 years after resection: report of a case. Clin J Gastroenterol (2013) 0.77
Matrigel induces L-plastin expression and promotes L-plastin-dependent invasion in human cholangiocarcinoma cells. Oncol Lett (2014) 0.76
Cutaneous Metastasis from Cholangiocarcinoma Presenting as Thigh Mass. J Clin Diagn Res (2016) 0.75
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. Int J Genomics (2015) 0.75
Liver resection for intrahepatic cholangiocellular carcinoma: when is it worthwhile? World J Surg (2008) 0.75
Is Surgical Resection Justified for Advanced Intrahepatic Cholangiocarcinoma? Liver Cancer (2016) 0.75
Predictors and patterns of recurrence after curative liver resection in intrahepatic cholangiocarcinoma, for application of postoperative radiotherapy: a retrospective study. World J Surg Oncol (2015) 0.75
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology (2001) 5.12
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.90
Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg (2001) 2.57
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg (2002) 1.75
Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg (1998) 1.72
Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol (2006) 1.65
A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer (2006) 1.56
Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg (2005) 1.32
Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery (2000) 1.25
Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg (2005) 1.18
An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg (2004) 1.15
Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg (2003) 1.09
Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg (2000) 1.06
Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg (2001) 0.99
Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastases. J Surg Oncol (2007) 0.94
Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg (1999) 0.90
Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol (2006) 0.85
Hepatopancreatoduodenectomy could be allowed for patients with advanced intrahepatic cholangiocarcinoma. Hepatogastroenterology (2007) 0.80
Do increases in mortality from intrahepatic cholangiocarcinoma reflect a genuine increase in risk? Insights from cancer registry data in Scotland. Eur J Cancer (2003) 0.79
Extended right hepatic lobectomy with resection of inferior vena cava and portal vein for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg (2000) 0.79
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med (2007) 12.62
D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med (2008) 9.00
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol (2011) 6.53
Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol (2004) 4.31
Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res (2009) 3.50
Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol (2006) 2.73
Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol (2003) 2.27
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell (2003) 2.20
Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci (2012) 1.98
Impact of energy devices during liver parenchymal transection: a multicenter randomized controlled trial. World J Surg (2015) 1.98
Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci (2008) 1.87
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res (2012) 1.84
Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg (2010) 1.72
Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci (2009) 1.64
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol (2008) 1.55
Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol (2011) 1.46
Relationship between the histological type of initial lesions and the risk for the development of remnant gastric cancers after gastrectomy for synchronous multiple gastric cancers. World J Surg (2010) 1.45
Predictors for early recurrence after hepatectomy for initially unresectable colorectal liver metastasis. J Gastrointest Surg (2013) 1.45
Primary gastric choriocarcinoma: two case reports and a pooled analysis of 53 cases. Gastric Cancer (2005) 1.44
A novel protein kinase B (PKB)/AKT-binding protein enhances PKB kinase activity and regulates DNA synthesis. J Biol Chem (2005) 1.40
Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol (2005) 1.40
Needle tract implantation of hepatocellular carcinoma and pancreatic carcinoma after ultrasound-guided percutaneous puncture: clinical and pathologic characteristics and the treatment of needle tract implantation. World J Surg (2003) 1.37
Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol (2009) 1.29
Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci (2012) 1.25
Survival benefits of portal vein resection for pancreatic cancer. Am J Surg (2003) 1.22
Long-term survival in two cases of resected gastric metastasis of pulmonary pleomorphic carcinoma. J Thorac Oncol (2008) 1.20
Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501). Ann Surg Oncol (2006) 1.19
Regulation of the plasma cell transcription factor Blimp-1 gene by Bach2 and Bcl6. Int Immunol (2008) 1.14
Laparoscopic proximal gastrectomy with jejunal interposition for gastric cancer in the proximal third of the stomach: a retrospective comparison with open surgery. Surg Endosc (2012) 1.06
Aggressive surgical treatment for T4 gastric cancer. J Gastrointest Surg (2004) 1.06
Extrahepatic spread from hepatocellular carcinoma: who are candidates for aggressive anti-cancer treatment? Jpn J Clin Oncol (2004) 1.05
Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact. Am J Surg Pathol (2007) 1.04
Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci (2013) 1.04
HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol (2008) 1.04
Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas (2004) 1.03
Long-term survival achieved by repeated resections of metachronous pulmonary and adrenal metastases of alpha-fetoprotein-producing gastric cancer: report of a case. Surg Today (2004) 1.02
The impact of liver metastasis on mortality in patients initially diagnosed with locally advanced or resectable pancreatic cancer. Int J Gastrointest Cancer (2003) 1.01
Prevention of postoperative pancreatic fistula after total gastrectomy. World J Surg (2008) 1.00
Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. Tohoku J Exp Med (2006) 0.99
Pancreas-sparing duodenectomy for duodenal neoplasms including malignancies. Hepatogastroenterology (2007) 0.98
Advanced pancreatic ductal cancer: fibrotic focus and beta-catenin expression correlate with outcome. Pancreas (2003) 0.98
Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2). Mol Pharmacol (2010) 0.98
Extrahepatic portal vein occlusion without recurrence after pancreaticoduodenectomy and intraoperative radiation therapy. Int J Radiat Oncol Biol Phys (2005) 0.97
FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Commun (2009) 0.96
Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int J Oncol (2011) 0.96
Solitary bile duct hamartoma of the liver. Scand J Gastroenterol (2005) 0.96